MOLECULAR THERANOSTICS, LLC
Beachwood, OH · Biotech · Private
Peptide drug conjugates targeting extradomain B fibronectin for tumor-specific delivery of chemotherapeutics to triple negative breast cancer
mtheranostics.com →- Grants
- $8.0M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Commercialization of targeted MRI contrast agents for prostate cancer imaging. | $249,874 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer. | $1,000,342 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization of an MRI contrast agent for differential diagnosis ofprostate cancer. | $2,083,047 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer. | $999,657 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer. | $1,450 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer. | $81,598 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer | $2,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of peptide drug conjugates for cancer therapy | $265,179 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · A peptide targeted fluorescence probe for precision surgery of head and neck cancer | $294,505 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1420 | Link Biosystems Inc. | — | — |
| 1421 | NEUMEDICINES, INC. | — | — |
| 1422 | Rectify Pharmaceuticals LLC | — | — |
| 1423 | MOLECULAR THERANOSTICS, LLC | — | — |
| 1424 | Prime Medicine | — | — |
| 1425 | Guide Star Biosciences, Inc. | — | $925K |
| 1426 | Gamma Therapeutics, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Extradomain B Fibronectin Targeting Peptides And Derivatives For Cancer Imaging And Therapyapplication
- Extradomain B Fibronectin Targeting Peptides And Derivatives For Cancer Imaging And Therapyapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.